Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.8552W HIGH $25.63
Volume
65.28 K
Value Traded
8.21 M
Short % Float
7.11%
-1.73%Week
-4.63%1 Month
+19.02%3 Month
+28.26%6 Month
-19.3%5 Year
-19.3%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
888.07 M
EPS (TTM)
-1.72
P/E Ratio
-
Ent. Value
758.81 M
Total Shares
38.39 M
Float Shares
25.57 M
Insiders
33.38%
Institutions
66.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CBLL Catalyst Timeline
Dated clinical, regulatory and corporate events for CeriBell, Inc.
Past FDA Catalysts and PDUFA Decisions
How CBLL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
CeriBell, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CBLL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Woo RaymondOfficer (Chief Technology Officer) | Option | 4,864 207,982 held | $3.65 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CBLL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 0.5 % | 7.52 M | 386.79 K |
CBLL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CBLL ranks across every disease it competes in
Competitive Position is a premium feature
See how CBLL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCBLL News
CBLLCeribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
Ceribell, Inc. has received FDA 510(k) clearance for new software enhancing its EEG platform. The update introduces features that simplify the interpretation of brain activity, aiding clinicians in timely decision-making. This software is designed for use across all age groups, from neonates to adults, and aims to improve patient outcomes in critical care settings.
Read more →CBLL▲ +10.4%on this news· ran to +21% by day 3
Ceribell Reports Second Quarter 2026 Financial Results
Ceribell, Inc. reported a strong financial performance for Q2 2026, with total revenue reaching $28.1 million, a 33% increase from the previous year. The company achieved a gross margin of 92% and received several FDA clearances for new products. Despite a net loss of $19.3 million, Ceribell raised its revenue guidance for the year, reflecting ongoing growth and adoption of its technology.
Read more →CBLLCeribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Ceribell, Inc. has received FDA 510(k) clearance for two AI enhancements to its Neurology Portal, aimed at improving electroencephalogram (EEG) assessments. The new features focus on Epileptiform Abnormality Detection and Artifact Reduction, addressing common challenges in EEG evaluation. These advancements are designed to streamline the review process and enhance diagnostic confidence for neurologists in critical-care settings.
Read more →CBLLCeribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a New Technology Add-on Payment for its Delirium Monitor System, allowing up to $2,171 per eligible Medicare patient. This follows the FDA clearance of the device, which aids in delirium screening and monitoring. The NTAP will take effect on October 1, 2026, enhancing access to this innovative technology for critically ill patients.
Read more →CBLLCeribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, Inc. has appointed Thomas West and Sharon O'Keefe to its Board of Directors, enhancing its leadership team as it expands its point-of-care brain monitoring platform. West brings extensive experience in scaling medical technologies, while O'Keefe has a strong background in health system management. Their appointments aim to further Ceribell's growth and innovation in neurological care.
Read more →CBLLCeribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
Ceribell, Inc. announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will highlight the company's innovative Ceribell System, which is designed for rapid diagnosis and monitoring of neurological conditions. A webcast of the presentation will be available on their website.
Read more →CBLLCeribell to Report Second Quarter 2026 Financial Results on August 10, 2026
Ceribell, Inc. has announced it will report its second quarter 2026 financial results on August 10, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Ceribell specializes in medical technology for neurological conditions and has developed an innovative EEG platform for acute care settings.
Read more →CBLLCeribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell announced the publication of a study in Critical Care Medicine demonstrating that its Clarity AI algorithm for measuring seizure burden correlates with neurological outcomes at discharge. The research involved 359 patients and highlighted that higher seizure burdens are linked to increased risks of severe disability and death. This advancement supports the need for real-time monitoring in critical care settings.
Read more →CBLL▲ +6.7%on this news
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, Inc. announced that its CEO, Dr. Jane Chao, will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The event will showcase Ceribell's innovative approach to diagnosing and managing serious neurological conditions through its FDA-cleared Ceribell System. A webcast of the presentation will be available on the company's website.
Read more →CBLLCeribell Reports First Quarter 2026 Financial Results
Ceribell, Inc. reported a strong financial performance for Q1 2026, with total revenue reaching $26.5 million, a 29% increase compared to the same quarter in 2025. The company also launched new neonate and pediatric products and received a proposed rule for reimbursement from CMS. However, operating expenses rose significantly, leading to a net loss of $19.7 million.
Read more →CBLL▼ -7.5%on this news
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, Inc. will participate in the Bank of America Securities 2026 Health Care Conference, featuring CEO Jane Chao and CFO Scott Blumberg in a fireside chat. The event is scheduled for May 13, 2026. Ceribell specializes in advanced diagnostic solutions for neurological conditions, with its FDA-cleared Ceribell System designed for acute-care settings.
Read more →CBLLCeribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. announced it will release its first quarter 2026 financial results on May 11, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. The Ceribell System, which aids in diagnosing neurological conditions, is FDA-cleared for use in critical care settings.
Read more →CBLLCeribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell, Inc. reported strong financial results for Q4 and full year 2025, with total revenue reaching $89.1 million, a 36% increase from 2024. The company expanded its seizure detection algorithm to include pediatric patients and anticipates continued growth in 2026. However, operating expenses rose significantly, contributing to a larger net loss compared to the previous year.
Read more →CBLLCeribell to Participate in Upcoming March Investor Conferences
Ceribell, Inc. has announced its participation in two upcoming investor conferences, enhancing its visibility within the industry. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, and both Scott Blumberg and CEO Jane Chao will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. The company focuses on innovative solutions for diagnosing and managing serious neurological conditions, emphasizing the capabilities of its FDA-cleared Ceribell System.
Read more →CBLLCeribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell, Inc. will announce its fourth quarter and full year 2025 financial results on February 24, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Ceribell specializes in medical technology for neurological conditions, with its FDA-cleared EEG system designed for rapid diagnosis and monitoring.
Read more →CBLLCeribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell, Inc. has been granted FDA Breakthrough Device Designation for its innovative Large Vessel Occlusion (LVO) stroke detection monitor. This device utilizes AI algorithms to analyze EEG signals, enabling early detection of LVO strokes in hospital settings. The designation underscores Ceribell's commitment to improving neurological care and addresses the critical need for timely stroke detection.
Read more →CBLL30/2025 Rebecca Robertson Board Chair Ceribell 360 N Pastoria Avenue Sunnyvale, CA 94085, USA Subject: Resignation from the Board of Directors Dear Rebecca Robertson and Members of the Board, Please accept this letter as
Lucian Iancovici, M.D., has announced his resignation from the Board of Directors at Ceribell, effective December 31, 2025. His decision is not due to any disagreements with the company's leadership or policies, but rather a personal choice to pursue other ventures. Dr. Iancovici expressed pride in the board's accomplishments during his tenure and committed to a smooth transition process. He has no outstanding claims against the company and will maintain confidentiality regarding sensitive information.
Read more →CBLLCeribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. (Nasdaq: CBLL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, led by CEO Jane Chao, Ph.D. The presentation will highlight the company's focus on improving diagnosis and management for patients with serious neurological conditions. The Ceribell System, a point-of-care EEG platform, has received FDA clearance and is designed for use in intensive care units and emergency rooms. The conference will feature a live and archived webcast accessible on the Ceribell website.
Read more →CBLLCeribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Ceribell, Inc. has received FDA 510(k) clearance for its innovative delirium monitoring solution, a first-of-its-kind device aimed at addressing the needs of critically ill patients. This AI-powered electroencephalography system enhances delirium detection and monitoring alongside seizure management. The solution is supported by extensive validation and aims to reduce healthcare burdens associated with delirium. Ceribell plans to finalize its go-to-market strategy to implement this technology effectively in clinical settings.
Read more →About CeriBell, Inc.
Headquarters360 N. PASTORIA AVENUE, SUNNYVALE, CA, 94085
BIOPHARMAWATCH ELITE PLUS
Trade the next CBLL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime